Dr. Narendranath Epperla, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 130
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35131559 -
Internal Medicine Physician
WI license 56327
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
Medical groups
- University of Utah Adult Services (1,788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 130
- Services billed
- 491
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 181 | 145 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 163 | 55 |
| Established patient office or other outpatient visit, 40-54 minutes | 114 | 63 |
| Hospital discharge day management, more than 30 minutes | 32 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 39 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Columbus, OH | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 28 payments worth $22,346 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $12,191 |
|---|---|
| AbbVie Inc. | $4,567 |
| Incyte Corporation | $2,446 |
| Genentech USA, Inc. | $1,956 |
| Celgene Corporation | $1,075 |
| Adc Therapeutics America, Inc. | $77.75 |
| Beone Medicines USA, Inc. | $32.52 |
| Consulting Fee | $19,842 |
|---|---|
| Travel and Lodging | $1,861 |
| Food and Beverage | $642 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Nov 10, 2025 | Consulting Fee | $11,938 |
| AbbVie Inc. Nov 26, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,398 |
| Genentech USA, Inc. Apr 16, 2025 | Consulting Fee Lunsumio · BioOncology | $1,882 |
| AbbVie Inc. Nov 11, 2025 | Consulting Fee | $725 |
| Celgene Corporation Sep 25, 2025 | Travel and Lodging travel to Lawrenceville Township, NJ | $661 |
| AbbVie Inc. Oct 25, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to MILLBRAE, CA · in-kind | $333 |
| E.r. Squibb & Sons, L.l.c. Nov 12, 2025 | Travel and Lodging travel to LAWRENCEVILLE TOWNSHIP, NJ | $230 |
| Celgene Corporation Sep 24, 2025 | Travel and Lodging travel to Lawrenceville Township, NJ | $189 |
| AbbVie Inc. Oct 24, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to MILLBRAE, CA · in-kind | $172 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,398 |
| AbbVie Inc. Nov 26, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| AbbVie Inc. Nov 26, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to SALT LAKE CITY, UT · in-kind | $148 |
| E.r. Squibb & Sons, L.l.c. Nov 12, 2025 | Travel and Lodging travel to LAWRENCEVILLE TOWNSHIP, NJ | $230 |
| AbbVie Inc. Nov 11, 2025 | Consulting Fee | $725 |
| E.r. Squibb & Sons, L.l.c. Nov 10, 2025 | Consulting Fee | $11,938 |
| AbbVie Inc. Oct 25, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to MILLBRAE, CA · in-kind | $333 |
| AbbVie Inc. Oct 24, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to MILLBRAE, CA · in-kind | $172 |
| Celgene Corporation Sep 25, 2025 | Travel and Lodging travel to Lawrenceville Township, NJ | $661 |
| Celgene Corporation Sep 25, 2025 | Travel and Lodging travel to Lawrence, NJ | $68.05 |
| Celgene Corporation Sep 25, 2025 | Travel and Lodging travel to Lawrence, NJ | $59.54 |
| Celgene Corporation Sep 24, 2025 | Travel and Lodging travel to Lawrenceville Township, NJ | $189 |
| Genentech USA, Inc. Apr 16, 2025 | Consulting Fee Lunsumio · BioOncology | $1,882 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $1,100,626 in research payments for these studies, mostly to the institutions running them.
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Ipsen Biopharmaceuticals, Inc · Active, not recruiting · NCT05551936 - A phase ii study of pirtobrutinib in combination with rituximab in newly diagnosed marginal zone lymphoma: a risk adapted approach
Lilly USA, LLC - A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Beone Medicines Ltd. · Recruiting · NCT06634589 - A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Ipsen Biopharmaceuticals, Inc · Active, not recruiting · NCT05934838 - IIT_EPPERLA_ADCT-402-2
Adc Therapeutics America, Inc. - A Phase II Study of Pemigatinib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Incyte Corporation - IIT_EPPERLA_ADCT-402-1
Adc Therapeutics America, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.